CL stock forecast, quote, news & analysis

Key Takeaways

• Colgate-Palmolive shares have risen approximately 3.9% over the past 30 days, reflecting steady accumulation in a defensive consumer staples name.
• The stock has gained roughly 8.4% over the last quarter, supported by strong Q1 2026 results that beat consensus estimates on both revenue and base business earnings.
• Q1 2026 net sales grew 8.4% year-over-year to $5.32 billion, while organic sales increased 2.9% with growth across all product categories.
• Analyst sentiment remains broadly constructive, with a consensus "Moderate Buy" rating and an average price target of approximately $97.41, implying additional upside from current levels.
• The upcoming Q2 2026 earnings report on July 31, 2026, stands as the next major catalyst for the stock.
• Colgate-Palmolive continues to pay uninterrupted dividends — a streak dating back to 1895 — with a current quarterly payout of $0.53 per share and a yield of roughly 2.3%.

Current Market Snapshot

Colgate-Palmolive Company (CL) closed at $92.98 on July 17, 2026, down 1.2% on the session but firmly positioned above both its 50-day and 200-day simple moving averages of approximately $90.46 and $88.54, respectively. The stock has carved out a measured upward trajectory in recent weeks, trading within a range that reflects the steady, low-beta character investors have long associated with this consumer staples giant. With a beta of just 0.33, CL has historically exhibited far less volatility than the broader market, making it a favored holding among institutional investors seeking reliable total return — 80.41% of outstanding shares are held by institutions. The stock's 52-week range of $74.54 to $99.33 underscores the meaningful recovery and compounding gains achieved over the past year, even as macroeconomic uncertainties persist globally.

Colgate-Palmolive (CL) Business Overview and Competitive Position

Colgate-Palmolive is one of the world's largest and most recognized consumer products companies, operating across four core segments: Oral Care, Personal Care, Home Care, and Pet Nutrition. The company's product portfolio spans everyday essentials — toothpaste, toothbrushes, mouthwash, soaps, body washes, deodorants, dishwashing liquids, surface cleaners, fabric softeners, and scientifically formulated pet foods — sold in more than 200 countries and territories. Iconic brands include Colgate, Palmolive, Ajax, Fabuloso, Softsoap, Irish Spring, Hill's Science Diet, Hill's Prescription Diet, and Tom's of Maine, among many others.

Colgate-Palmolive commands dominant global market share in its flagship oral care category, with year-to-date 2026 toothpaste market share at 41.1% and manual toothbrush share at 32.6%. International markets account for roughly 70% of total sales, with significant exposure to Latin America, Asia-Pacific, Europe, and Africa/Eurasia. The company's pet nutrition division, anchored by Hill's, represents approximately 22.6% of total revenue and is a global leader in veterinary-recommended pet food. This diversified revenue base — spanning geographies, product categories, and price tiers — provides a durable competitive moat that has enabled Colgate-Palmolive to pay uninterrupted dividends since 1895.

Recent Developments Driving CL

Several factors have shaped investor sentiment around CL in recent weeks. On May 1, 2026, the company reported Q1 2026 earnings that surpassed Wall Street expectations: base business earnings per share came in at $0.97, exceeding the consensus estimate of $0.94, while revenue of $5.32 billion topped the $5.22 billion consensus. Organic sales grew 2.9%, with Chairman and CEO Noel Wallace highlighting broad-based growth across every category and four of five geographic divisions.

Analyst activity has been notably constructive. JPMorgan reaffirmed its Overweight rating and raised its price target to $104 from $96 on July 16, 2026. Piper Sandler lifted its target to $96 with an Overweight rating on July 9. Citigroup raised its target to $110 with a Buy rating. Wells Fargo increased its target to $95 while maintaining an Equal Weight stance. Overall, twelve analysts rate CL a Buy against seven Holds, with the average target of $97.41 suggesting room for appreciation.

On the corporate governance front, Colgate-Palmolive declared its regular quarterly dividend of $0.53 per share, payable August 14, 2026, to shareholders of record on July 20, 2026. The company has also scheduled its Q2 2026 earnings conference call for July 31, 2026, which will provide the next comprehensive update on organic sales trends, margin performance, and full-year guidance. Institutional activity has been active, with notable position increases from Principal Financial Group, Wealthfront Advisers, and Mediolanum International Funds, partially offset by position reductions from CalPERS.

Trending AI Robots

Investors seeking data-driven tools to navigate markets like the consumer staples sector may find value in exploring Tickeron's curated Trending AI Robots page. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of tickers across diverse strategies and timeframes, but only the top-performing and most relevant bots are featured in this curated section. Each bot employs distinct algorithms, risk parameters, and performance metrics — ranging from short-term momentum strategies to longer-term trend-following approaches — allowing users to evaluate bots that align with their own trading style and objectives. For those tracking stocks like Colgate-Palmolive within the consumer defensive space, these AI-driven tools offer an additional lens through which to monitor market signals and evolving trading patterns.

2026 Outlook and What Investors Should Watch

Looking ahead, the Q2 2026 earnings report on July 31 represents the most immediate and consequential event for CL shareholders. Analysts expect Q2 earnings per share of approximately $0.96 on revenue near $5.31 billion, and any deviation — particularly around organic sales growth, gross margin trajectory, and geographic performance — will likely drive near-term price action. Full-year 2026 consensus estimates project earnings of approximately $3.86 per share on revenue of roughly $21.24 billion.

Broader macroeconomic factors remain critical. Persistent currency headwinds, input cost inflation, and varying rates of category growth across global markets present ongoing challenges that management has acknowledged. The company's 2030 strategy emphasizes consistent compounded earnings per share growth, and investors will closely monitor whether second-half 2026 performance stays on track against these long-term targets. Competitive dynamics in oral care — where Colgate's 41.1% global toothpaste share leads the industry — and the growth trajectory of the Hill's Pet Nutrition division are also key themes. Additionally, the consumer defensive sector's relative appeal in an uncertain economic environment may continue to provide a tailwind for low-beta, dividend-paying equities like CL, though elevated valuation levels — the stock trades at roughly 24 times forward earnings — mean execution must remain precise.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.